Q-omics provides the consensus-scored TMEM175 profile across patient tissues and cancer cell-line models. TMEM175 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM175 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, TMEM175 RNA expression shows 18,222 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, LIHC, and KIRP as cancer lineages where TMEM175 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM175 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM175 survival associations across molecular data types. TMEM175 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM175 RNA expression–survival associations across cancer types. High TMEM175 expression shows unfavorable associations in UVM, KIRC and LUSC, but favorable associations in PAAD, UCEC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM175 RNA expression.
This table summarizes TMEM175 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM175. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM175 shows lower tumor expression in THCA and LUSC and higher tumor expression in LIHC, ESCA, CHOL and STAD. The LIHC box plot shows higher TMEM175 RNA expression in tumor versus normal tissue (log2 FC = +0.926, t-test p < 0.001).
This table shows molecular features associated with TMEM175 in patient tissues and cancer cell lines. In patient samples, TMEM175 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM175 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
